MedPath

KANJINTI

KANJINTI

Approved
DIN Number

02518244

Drug Class

Human

Market Date

Oct 7, 2021

Company
HC

Amgen Canada Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02518244
AIG Number0154252002
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription ,  Schedule D
A
ATC Code
L01FD01 TRASTUZUMAB
Product Specifications
Dosage FormPowder For Solution
Route of AdministrationIntravenous
AHFS Classification10:00.00
Health Canada Classification

ACTIVE INGREDIENTS (1)

TRASTUZUMABActive
Strength: 150 MG / VIAL
Monograph: TRASTUZUMAB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.